FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the use of recombinant antibodies that specifically bind human proprotein convertase of subtilisin/kexin type 9 (PCSK9); it can be used in medicine for the treatment of patients with a high cardiovascular risk, suffering from hypercholesterinemia and diabetes mellitus type 1 or 2, receiving a therapeutic agent based on insulin.
EFFECT: invention allows for safe and effective reduction in the LDL-C level in patients with diabetes mellitus type 1 or 2 that have a high cardiovascular risk and a high LDL-C level despite the treatment with the maximum tolerated dose of statins.
19 cl, 5 dwg, 16 tbl, 3 ex
| Title |
Year |
Author |
Number |
| HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING SPECIFIC GROUPS OF INDIVIDUALS |
2012 |
- Hanotin, Corinne
- Bessac, Laurence
- Chaudhari, Umesh
|
RU2721279C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE |
2018 |
- Tian, Chenmin
- Li, Hao
- Liu, Xun
|
RU2782792C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF |
2016 |
- Tsyuj, Syandun
- E, Sin
- Syuj, Shaoyu
- Yuan, Bej
- Tsuj, Dunbin
- Khu, Tsiyue
- Chzhan, Lej
- Syuj, Chzhibin
- Tao, Vejkan
- Chzhan, Lyanshan
- Sun, Pyaoyan
|
RU2739208C2 |
| AGONISTIC ANTIBODY TO LEPTIN RECEPTOR FOR USE IN TREATMENT OF METABOLISM DISORDERS OR HYPOLEPTINEMIA |
2019 |
- Gromada, Dzhesper
- Stevis, Panajotis
- Altaredzhos, Dzhudit
- Merfi, Endryu Dzh.
|
RU2812670C2 |
| ANTI-PCSK9 ANTIBODY AND ITS APPLICATION |
2016 |
- Wu Hai
- Chen Bo
- Feng Hui
- Yao Sheng
- Yao Jian
- Liu Hongchuan
- Zhang Libo
- Zhang Jing
- Meng Dan
|
RU2756012C2 |
| METHODS FOR TREATMENT OF SEVERE INSULIN RESISTANCE BY INTERRUPTING GLUCAGON RECEPTOR SIGNAL TRANSMISSION |
2017 |
- Gromada, Dzhesper
- Okamoto, Haruka
- Jaspers, Stephen
- Harp, Joyce
|
RU2772508C2 |
| DOSING STRATEGY REDUCING CYTOKINE RELEASE SYNDROME FOR CD3/C20 BISPECIFIC ANTIBODIES |
2019 |
- Brownstein, Carrie
- Lowy, Israel
- Adriaens, Lieve Lucille
|
RU2799529C2 |
| ANTI-MET ANTIBODIES AND THEIR USE |
2017 |
|
RU2765267C2 |
| PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF REDUCING OR LOSING ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED COAGULATION FACTOR VIII |
2015 |
|
RU2721910C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES |
2019 |
- Lala, Mallika
- Dzhejn, Lokesh
- Li, Mengiao
- Altura, Rejchel Ellison
- Tse, Archi Ngaj-Chiu
|
RU2825835C2 |
